BACKGROUND

The Maryland Prescription Drug Affordability Board may request information to conduct a cost review study under Health-General Article, §21-2C-09(a)(2), Annotated Code of Maryland, and COMAR 14.01.04.04.A.(2). The data points requested in the insurer data submission request form (excel) are in accordance with COMAR 14.01.04.04.B.(2).

INSURER REQUEST INSTRUCTIONS

Insurers are encouraged to provide information on as many data elements for all applicable 11-digit National Drug Codes (NDC-11). If the submitter completing this file opts to only submit information at the aggregate level for the drug product under review, please check the box below.

☐ Submission of Aggregate Information Only

Respondents may provide the requested information via the following:

- a. Utilizing the tables provided at the end of this form in appendices A-E.
- b. Utilizing the supplemental excel file provided with this form.
- c. Directly typing data in each applicable section.
- d. Providing documentation in any form that the respondent deems suitable.

For any questions regarding the data submission request form, please reach out to

Part 1: Contact, Drug, and Insurer Information

Please provide the name and contact information of an individual who will be able to answer questions regarding the information submitted in this form.

Contact Information			
Name of Insurer			
Contact Name			
Contact Title			
Email Address			
Telephone Number			
Street Address			
City			
State			
Zip Code			

Provide the information requested in the table below about the prescription drug product under review. In this table, submitters should provide the non-proprietary and brand name of the drug selected for Cost Review. Additionally, submitters should provide all applicable 11-digit National Drug Codes (NDC-11) related to the selected drug, separated with a semicolon.

General Drug Information				
Non-Proprietary Drug Name				
Brand Name				
National Drug Code(s) (NDC-11)*				
*If there are multiple NDC-11s, please provide a description of each, including information on				
dosage and package size. Please separate each NDC with a semicolon.				

Below, please indicate the number of plans offered by the insurer.

Insurer Information		
Number of Plans Offered by Insurer		

Data Dictionary

The following table reflects the requested data elements along with their respective regulatory authority. The table also notes the applicable section where each data element should be populated.

Requested Data Points	Regulatory Citation	Applicable Sheet
Placement in each formulary offered or	14.01.04.04.B(2)(c)	Plan Information
administered in the State and the number of		and Costs
covered lives for each formulary		
Benefit design around the prescription drug	14.01.04.04.B(2)(d)	Plan Information
product, including copayment and coinsurance		and Costs
amounts in the State;		
The net cost incurred by the insurance carrier for	14.01.04.04.B(2)(e)	Plan Information
the prescription drug product in the State		and Costs
The total amount of the price concessions,	14.01.04.04.B(2)(a)	Plan Information
discounts, and rebates the manufacturer provides		and Costs
to each health plan operating in the State,		
expressed as a percent of the WAC		
The average price concession, discount, and rebate	14.01.04.04.B(2)(b)	Therapeutic
provided in the State for therapeutic alternatives		Alternative
Any additional factors or information the health	14.01.04.04.B(2)(f)	Submit as
insurance carrier, HMO, or MCO proposes that the		documentation
Board consider		

Part 2: Plan Information and Costs

Provide best estimates for the following plan and cost-related information listed below for the drug product under review. Data elements populated within this sheet should be reported specifically for each NDC-11 (or aggregate drug product) according to the plan (i.e., plan ID) offered by the insurance company.

- 1. Plan ID
- 2. Placement in Formulary (i.e., Tier)
- 3. Brief Explanation of the Formulary Tiers (i.e., specify the number of tiers offered within the plan)
- 4. Number of Covered Lives for Each Formulary in Maryland
- 5. Benefit Design Copay Amounts in Maryland
- 6. Benefit Design Coinsurance Amounts in Maryland
- 7. The Net Cost Incurred by the Insurance Carrier (i.e., plan) for the Prescription Drug Product in Maryland
- 8. The Total Amount of Price Concessions, Discounts, and Rebates the Manufacturer Provides to Each Health Plan Operating in the State, Expressed as a Percent of the Wholesale Acquisition Cost (WAC)

A table template for populating the requested information can be found in **Appendix A**.

Part 3: Therapeutic Alternative(s)

Insurers are requested to provide information regarding therapeutic alternative(s) for the prescription drug product under review. Each therapeutic alternative should be identified by its non-proprietary and brand name. Insurers should provide best estimates of *The Average Price Concession*, *Discount*, and *Rebate Provided in Maryland for the Identified Therapeutic Alternative*.

Information on price concessions, discounts, and rebates in Maryland requested in this section should be reported specifically for each NDC-11 and each plan for a single therapeutic alternative. If the insurer identifies multiple therapeutic alternatives associated with the prescription drug of interest, they should provide the requested information for each.

A table template for populating the requested information can be found in **Appendix B**.

SUBMISSION OF ADDITIONAL DOCUMENTATION

Insurance carriers, HMOs, or MCOs completing the Maryland PDAB's data submission requests are encouraged to provide additional documentation for other factors that they believe the Board should consider.

Appendix A. Plan Information and Costs

Plan Information						
NDC-11*	Plan ID	Placement in	Explanation of	Number of	Benefit design	Benefit design
		Fomulary	Formulary Tiers	covered lives for	around the	around the
				each formulary	prescription	prescription
				in the state	drug product -	drug product-
					copay amounts	coinsurance
					in the State	amounts in the
						State

^{*}If submitting aggregate information, please provide the non-proprietary drug name in place of the 11-digit NDC. Please insert as many rows into this table as needed.

	Cost Information				
prescription drug product in the State rebates the manufacturer provides to each health place operating in the State,	NDC-11*	Plan ID	insurance carrier for the prescription drug product in	provides to each health plan operating in the State, expressed as a percent of the	

^{*}If submitting aggregate information, please provide the non-proprietary drug name in place of the 11-digit NDC. Please insert as many rows into this table as needed.

Additional Information

In a narrative format, use the space below to provide additional information on the calculation methods, assumptions, interpretations, and caveats related to the data requested in this section of the appendix.

Appendix B. Therapeutic Alternative Information

Therapeutic Alternative # 1					
Therapeutic Alternative Non-Proprietary Name	Therapeutic Alternative Brand Name	NDC-11*	Plan ID	The average price concession, discount, and rebate provided in the State for therapeutic alternatives	

^{*}If submitting aggregate information, leave the NDC-11 column blank. Please insert as many rows into this table as needed and make copies of this table template for any additional therapeutic alternatives identified by the insurer.

Additional Information

In a narrative format, use the space below to provide additional information on the calculation methods, assumptions, interpretations, and caveats related to the data requested in this section of the appendix.